Library

Place of publication:
Journal of Neurology and Psychiatry, 4, 2018

Summary:
Purpose of the study. Assessment of the effectiveness and tolerance of the drug Mexidol as a corrector of cognitive disorders in patients with arterial hypertension and clinical manifestations of chronic cerebrovascular accident. Material and methods. 42 patients with clinical manifestations of chronic brain ischemia (chemical) and cognitive disorders were examined. Patients of the 1st group (n = 21) received traditional antihypertensive therapy, patients of the 2nd group (n = 21)-antihypertensive drugs and Mexidol. To evaluate the neuropsychological status, MMSE, Mosa, Mosa, Watch Drawing West were used. To control the adherence to therapy, a survey was carried out using the Morisk -Grine test. Results and conclusion. After the course of treatment with Mexidol, the number of patients with a lack of complaints increased by 3 times, headache regression was noted in 90% of patients, improving memory, concentration of attention, and the disappearance of anxiety in 50, 55, 67%, respectively. In patients of the 2nd group (Mexidol), more significant changes have occurred for the watch drawing test compared to the 1st group (0.95 and 0.54 points, And Mosa, which indicates the effective effect of the drug on cognitive symptoms of neurodynamic type and well -being in patients with chemical genesis. The drug Mexidol is recommended for the use of patients in this group as part of the complex therapy of the underlying disease. Key words: Mexidol, cognitive impairment, commitment.

Place of publication:
Journal of Neurology and Psychiatry, 2, 2018

Summary:
Purpose of the study. Track the dynamics of biochemical markers of inflammation and indicators of damage to the brain tissue in the acute period of ischemic stroke (AI) in the background of taking submaximal doses of the drug Mexidol. Material and methods. The study included 60 patients received in the first 6 hours from the onset of the disease, with verified AI on the Aspects scale 7–9 points. Patients of the main group (n = 30) received submaximal doses of Mexidol - 750 mg of the drug diluted in 250.0 ml of physiological solution, 2 times a day intravenously for 6 days. Patients of the control group (n = 30) were prescribed standard therapy. All patients were determined by biomarkers, an assessment of the neurological status within 60 minutes from the moment of receipt to the hospital and on the 7th day. Results and conclusion. In both groups, the indicators of the C-reactive protein, Interleukin-6 and fibrinogen changed slightly and did not have reliable significance in assessing the effectiveness of Mexidol. The indicators of biomarkers such as brainwater peptide and pretein plasma-A protein-A, as well as the average indicators in the NIHSS and MFI-20 scales in a group of patients receiving Mexidol, have significantly decreased compared to the control group. The results indicate a decrease in oxidant stress and signs of inflammation in the acute period of AI against the background of submaximal doses of the drug Mexidol, a decrease in the severity of neurological deficiency, and an increase in physical activity of patients. Given the time of activation of the damaged antioxidant system of the body, the recommended period of drug support is 3 months. Key words: antioxidant stress, inflammation, acute period, ischemic stroke, Mexidol.

Place of publication:
journal neurology, neuropsychiatry, psychosomatics, 1, 2018

Summary:
in elderly patients, dizziness can be caused by various causes, the possibilities of drug therapy are limited, the most commonly used are the betagistine of digidloride. The purpose of the study is to study the effectiveness and safety of complex therapy with Mexidol ^® and betagistin in patients with dizziness according to the global evaluation of the effectiveness of treatment. Patients and methods. The study includes 89 elderly patients (average age - 73.7 years) with chronic cerebrovascular pathology and dizziness complaints. In all patients, neurological, otoneurological (orthostatic samples, with forced hyperventilation, dix - medalpike, tinetti, visual analogue of dizziness), somatic, cognitive and emotional status. Patients were randomized into two groups. The main group included patients who received a betagistin of 48 mg/day, Mexidol ^® 5.0 ml intravenously for 10 days, then 375 mg/day tablets; In the comparison group - patients who used only 48 mg/day betagistine for 60 days. Assessment of the effectiveness of treatment was carried out on a global scale on the 60th day of therapy in both groups, taking into account the opinion of the doctor and the patient. Results. In elderly patients, dizziness in most cases (75%) was caused by several causes. In a group of combined treatment (betagistin + Mexidol ^® ), a more significant (more than doubled) decrease in dizziness symptoms are noted than in the comparison group. Conclusion. In elderly patients with chronic cerebrovascular disease and dizziness, combined therapy with Mexidol ^® and betagistin with neuroprotective properties improves treatment results.

Place of publication:
a journal of neurology and psychiatry, 3, 2017; Ext. 2

Summary:
Purpose of the study. To evaluate the effectiveness and safety of prolonged sequential therapy with Mexidol with patients with hemispherical ischemic stroke (AI) in acute and early recovery periods. Material and methods. In a randomized double-centered placebo-controlled in parallel groups, the study included 151 patients (62 men and 89 women), 150 patients (62 men and 88 women) aged 40 to 79 years were randomized. Patients by simple randomization were distributed to 2 groups: patients of the 1st group received therapy with Mexidol of 500 mg/day intravenously for 10 days, followed by 1 tablet (125 mg) 3 times a day for 8 weeks. Patients of the 2nd group received a placebo according to a similar scheme. The duration of participation in the study was from 67 to 71 days. Results. At the time of the end of the therapy, the average score on the modified scale of Rankin (MSHR) was lower in the 1st group than in the 2nd (p = 0.04). The dynamics of reducing the average score according to MSHR (1-5th visit) was more pronounced in the 1st group (p = 0.023). The proportion of patients who have reached the recovery corresponding to 0-2 points in MSHR (5th visit) was significantly higher in the 1st group (p = 0.039). When testing on a stroke scale of the National Institute for Health to the 5th visit, the average value was lower in the 1st group (p = 0.035). A decrease in the score on the stroke scale of the National Institute for Health at the time of the end of the course of therapy regarding the initial level in patients with diabetes was more pronounced in the 1st group (p = 0.038). In the 1st group in the general population of patients and subpopulation of patients with diabetes, the dynamics of improving the quality of life was more pronounced and was observed from the 2nd visit. The proportion of patients with the lack of problems in space was significantly higher in the 1st group (p = 0.022). There were no reliable differences in the frequency of unwanted phenomena in patients of both groups. Conclusion. It is recommended that the use of Mexidol in the acute and early recovery periods of AI is recommended.

Place of publication:
Stroke, 18, 2006

Summary:
patients with an ischemic stroke at the age of 45–85 years (51 people) entered the first 24 hours from the onset of the disease were included in the study. Mexidol was introduced at a dose of 300 mg/day 24 patients for 14 days from the beginning of the stroke. The placebo was introduced by 27 patients according to a similar scheme. A reliable advanced dynamics in the regression of neurological disorders on the NIH scale by the 14th day of the disease in the group of patients who received Mexol compared to the placebo group (p <0.05), as well as a reliable functional restoration (the dynamics of the clinical score on the Bartel scale at 21, were identified. -y day; p <0.05) in patients included in the study in the first 6 hours of the disease. The normalization of the functional activity of the brain was established in the treatment of Mexidol, including during acute pharmacological test. The complex of studies of the antioxidant system revealed an increase in the activity of its enzymes (superoxidsmutase, glutathioneperoxidase, glutathioneuctase) with the introduction of Mexidol compared to placebo. When analyzing the enzymes of the respiratory chain of mitochondria, an increase in the activity of succinate dehydrogenase was noted. Thus, a reliable clinical confirmation of the effectiveness of Mexidol was obtained in the acute period of ischemic stroke in the carotid system of an atherotrombotic or cardiembolic pathogenetic type, especially with an early (up to 6 hours) its appointment; The mechanisms of action of the drug (antihypoxic, antioxidant) in clinical conditions are clarified.

Place of publication:
Journal of Neurology and Psychiatry, 5, 2016

Summary:
Purpose of the study. The study of the influence of the combination of Mexidol and Cerebrolysin as part of complex therapy on the state of the clinical status of patients with chronic brain ischemia (chemical) stage II on an outpatient basis. Material and methods. The study includes 36 patients with a diagnosis of stages II. Against the background of basic therapy, patients received 2 courses of combined therapy with Mexidol and Cerebrolysin for 6 weeks with an interval between courses of 3 months. After each course, the dynamics of patient complaints and objective clinical manifestations were evaluated. After the end of the treatment, the content of 13 chemical elements in the hair is determined by the atomic-emission method. Results and conclusion. Based on the clinical and neurological examination, the therapeutic effectiveness of the appointment of Mexidol and Cerebrolysine as a long neuroprotement in patients with the II stage, which was manifested by a reliable decrease in the severity of all the main symptoms under the influence of the therapy, is shown.

Place of publication:
Journal of Neurology and Psychiatry, 2, 2016

Summary:
The purpose of the study is to determine the effectiveness of Mexidol therapy to optimize the secondary prevention of vascular events through exposure to the indicators of vascular-trombocyte hemostasis and lipid blood spectrum in patients who have suffered ischemic stroke (AI), against the background of type 2 diabetes (SD2). Material and methods. Conducted a study of the content of general cholesterol, low -density lipoproteins, high density lipoproteins, blood -triglycerides in blood serum; The concentrations of the 4-plastic factor (4PF), β-tromboglobulin (βTH) and the villebrand factor in 68 patients with AI and SD2 were determined. Dynamic control of the studied indicators was carried out (1st, 21st day, 3rd and 6th months from the beginning of AI) amid therapy with Mexidol. Results and conclusion. Prolonged Mexidol therapy provides additional opportunities for normalizing the lipid blood spectrum and optimize secondary prevention of vascular events in patients with AI and SD2.

Place of publication:
Journal of Neurology and Psychiatry, 2, 2015

Summary:
Purpose of the study. Analysis of the effectiveness and safety of the use of Mexidol and its impact on the dynamics of neurological manifestations of the disease, the emotional status and quality of life in patients with chronic brain ischemia (chemical). Material and methods. 45 patients with chemicals received Mexidol of 500 mg iv a drop 1 time per day for 14 days, followed by an oral reception of 500 mg (2 tablets 2 times a day) for 60 days. The comparison group consisted of 30 patients with chemicals, comparable by age, the presence of risk factors and the severity of neurological manifestations that did not accept Mexidol. Patients of both groups received basic therapy, including drugs to achieve the complete correction of their risk factors. Assessed the state of cognitive functions (MMSE questionnaire), motor activity, quality parameters (SF-36). Results. By the end of the study (on the 74th day), patients of the main group compared with the comparison group, the severity of motor activity disorders has significantly reduced, the indicator of the assessment with the recount of utility on the SF-36 scale was normalized, and a reliable improvement of the average indicators of the screening estimate of cognitive functions was noted (MMSE). When analyzing the results of the study, the high efficiency and safety of the treatment of patients with a chemous drug Mexidol was confirmed.

Place of publication:
Journal of Neurology and Psychiatry, 3, 2014

Summary:
The purpose of the study is to analyze the effectiveness of the drug Mexidol in relation to the secondary prevention of ischemic stroke (AI). Material and methods. The results of the treatment of 3400 patients who were divided into 7 groups are analyzed: patients with cryptogenic AI, arterial hypertension, atrial fibrillation, metabolic syndrome, obstructive apnea/sleep hypnome, diabetes mellitus, vasculitis. Assessment of the effectiveness of therapy was based on the absence of repeated AI for 5 years of therapy. Results. Mexidol helps to reduce the frequency of repeated AI in both patients without concomitant pathological conditions, and in patients with arterial hypertension, obstructive apnea/sleep hypnome syndrome, vasculitis, diabetes mellitus, atrial fibrillation and metabolic syndrome. Conclusion. Further studies of the effectiveness of the use of Mexidol as a means of secondary prevention of AI are seemed very promising. Key words: stroke, secondary prevention, Mexidol.

Place of publication:
emergency medical care, 2, 2013

Summary:
114 patients with an isolated severe traumatic brain injury aged 18 to 55 years were examined and treated. The group I includes 61 surviving patient, in the II group-53 patients who died on the 3-and -15th day of the post-traumatic period. Patients of groups I and II received complex intensive therapy in accordance with the current protocols. Fifteen patients (subgroup I) were obtained as part of the complex therapy of Mexidol at a dose of 1200 mg/day for 7-10 days. Against the background of the use of Mexidol, the intensity of the processes of lipoperoxidation was reduced, the power of the cell antioxidant protection system remained at a sufficient level, and the earlier resolution of post -traumatic encephalopathy and the restoration of consciousness were observed. Against the background of treatment with Mexidol, a more favorable course of the early post-traumatic period, a decrease in complications (χ2 = 55.4; p <0.0001)-acute damage syndrome, DIC, acute cardiovascular failure and pneumonia are noted.

Place of publication:
Pharmacate No. 19 - 2012

Summary:
In a study that included 34 patients, the effectiveness of Mexidol's preparation in the correction of astheno-vegetative disorders was studied in persons who have suffered a mild craniocre trauma (LCHMT) and a concussion of the brain. The use of Mexidol as part of the complex therapy of these disorders made it possible to improve the results of treatment compared to the control group of patients who did not receive Mexidol. It is noted that the prescription of the drug is preferably at an earlier date from the moment of injury. A distinct therapeutic effect was obtained when using Mexidol in a daily dose of 375 mg in a tablet form for 28-30 days in the acute and intermediate periods of the LCCMT. Side effects and complications during therapy were not observed in any group. It is concluded that Mexidol can be used in the complex treatment of LCHMTs, a concussion of the brain and the correction of the post -compliance syndrome.

Place of publication:
Journal of Neurology and Psychiatry, 6, 2012

Summary:
in the structure of cerebrovascular pathology, the stroke occupies a leading place as one of the main causes of mortality and primary disability of the population. In the treatment of a stroke, in the acute period, measures are the measures to correct the impaired functions of the body and maintain the viability of the nervous tissue. In the recovery period, drugs are used that have an activating effect on neurotrophic and reparative processes, and secondary prophylaxis of stroke is carried out. It is known that brain ischemia is a multifactor pathological process that includes a decrease in energy products with a violation of active vehicles through cell membranes, excessive accumulation of excitoxic excitation mediators in brain structures, an increase in ionized calcium in neurons, hyperproduction of free radicals and activation of oxidant stress. To correct these changes, preparations with antihyplance and antioxidant properties are traditionally used, which include Mexidol (2-ethyl-6-methyl-3-hydroxypyridine succinate). Mexidol improves the metabolism of nervous tissue, it is also known that it affects the rheological properties of blood, reduces platelet aggregation, and has a hypolipidemic effect.

Place of publication:
Herald of intensive therapy, 2012, No. 3. Neuroreusterology

Summary:
annually in the world from a traumatic brain injury (ChMT), one and a half million people die, and 2.4 million become disabled. The frequency of the CCT in various regions of Ukraine is from 2.3 to 4.2% per year, and over the past 10 years has almost doubled. Missiles for a severe CCT is 40–70%, and in surviving patients, the full functional restoration of the central nervous system (central nervous system) is relatively rare.

Place of publication:
Medical alphabet. Emergency medicine 1/22

Summary:
Heddle-brain injury (ChMT) is one of the main reasons for the disability and death of the population. Moreover, mechanical damage to the central nervous system does not tend to decrease in the structure of diseases and injuries. According to WHO, the frequency of craniocre injury annually increases by 2%. In Russia, about 600,000 people receive a traumatic brain injury annually, of which about 50,000 die and the same number of disabled people (Gusev E.I., 2009). Mortality at a severe CMT, according to various estimates, ranges from 10 to 25%, and with the most severe forms reaches 65-70%. In the vast majority of victims (60%), a decrease in performance and disability (epileptic seizures, encephalopathy, paresis and paralysis, speech disorders and other neurological consequences) are observed as a result of injury.

Place of publication:
Bulletin of experimental biology and medicine, 2012, Appendix 1

Summary:
the use of Mexidol in a basic dose of 100 mg/day intramuscularly for 10 days is effective in the treatment of mild CITs, which is confirmed by positive neurological dynamics. In patients with a severe CCT, it is more advisable to use a 10-day treatment regimen with a mexidol at a dose of 200 mg/day intramuscularly with the subsequent transition to orally in a dose of 0.25 g 2 times a day for 4 weeks. Due to the good tolerance and the possibilities of intramuscular administration, Mexidol is an urgent drug in outpatient practice for the treatment and rehabilitation of patients of different age groups with the CCT.

Summary:
intracranial hypertension syndrome (HDG) with distant consequences of closed cranial injury (CSMT) is manifested by organic and functional disorders of varying degrees of severity. The work uses a method for assessing the degree of ICG by measuring distances between the structures of the brain stem using magnetic resonance imaging. The calculation of the restriction index of the posterior cranial fossa made it possible to compare the data of 96 patients with the HRG, some of which received Mexidol, and 28 healthy volunteers. Observation was carried out during the year with a neurological examination in dynamics. A comparison of groups of patients with each other and with indicators of healthy individuals revealed reliable differences expressed to a lesser extent of the NCH after treatment with Mexidol. The study showed that the prolonged course use of Mexidol is an effective method of preventing episodes of increasing intracranial pressure in the remote period of mild ZchMT and can be recommended for wide use both in stationary and outpatient conditions.